AVITA Medical Successfully Completes Australian Equity Raise
Rhea-AI Summary
AVITA Medical (NASDAQ: RCEL) has successfully completed a private placement in Australia, raising approximately US$15 million (A$23 million) through the issuance of 17.2 million new CHESS Depositary Interests (CDIs). The placement was priced at A$1.32 per CDI, representing an 11% discount to the last closing price of A$1.48.
The funds will be utilized for working capital requirements and strategic flexibility to support the company's therapeutic acute wound portfolio growth. AVITA Medical expects this capital to sustain operations until it achieves free cash flow in 2026. The new CDIs are scheduled for settlement on August 19, 2025, with trading on the ASX commencing August 20, 2025.
Positive
- None.
Negative
- 11% discount to market price indicates dilution for existing shareholders
- Additional equity raise suggests current cash position needs reinforcement
News Market Reaction 29 Alerts
On the day this news was published, RCEL gained 14.76%, reflecting a significant positive market reaction. Argus tracked a peak move of +28.0% during that session. Our momentum scanner triggered 29 alerts that day, indicating elevated trading interest and price volatility. This price movement added approximately $20M to the company's valuation, bringing the market cap to $157M at that time. Trading volume was elevated at 2.1x the daily average, suggesting notable buying interest.
Data tracked by StockTitan Argus on the day of publication.
- Private placement of approximately 17.2 million new CHESS Depositary Interests (“New CDIs”) quoted on the Australian Securities Exchange (ASX)
- Issue price of A
$1.32 per New CDI, raising approximately US$15 million (~A$23 million ), with participation from new and existing Australian shareholders
VALENCIA, Calif., Aug. 12, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (ASX: AVH, NASDAQ: RCEL), a leading therapeutic acute wound care company delivering transformative solutions, today announced the successful completion of a private placement (the “Placement”) to institutional and professional investors in Australia to raise an approximate gross amount of US
Proceeds from the Placement will be used for working capital requirements and will provide additional strategic flexibility to support continued growth of the Company’s therapeutic acute wound portfolio. This is expected to cover operations until free cash flow begins in 2026.
“The strong support we received in this Placement reflects growing confidence in our strategy and the transformative potential of our therapeutic acute wound care portfolio,” said Jim Corbett, Chief Executive Officer of AVITA Medical. “We welcome our new Australian shareholders and extend our sincere gratitude to our existing investors for their continued support.”
MST Financial Services Pty Limited acted as sole lead manager.
Placement Details
The Company will issue approximately 17.2 million New CDIs under the Placement at the Offer Price of A
The New CDIs are being issued by the Company in accordance with the Company’s available placement capacity pursuant to ASX Listing Rule 7.1.
The New CDIs are expected to be settled on August 19, 2025, and to be allotted and to commence trading on the ASX shortly thereafter on August 20, 2025. New CDIs issued under the Placement will rank equally with the Company’s existing CDIs on issue.
Indicative Timetable*
| Event | Date |
| Launch of Offer | Tuesday, August 12, 2025 |
| Announcement of completion of Placement | Wednesday, August 13, 2025 |
| Settlement of New CDIs under the Placement | Tuesday, August 19, 2025 |
| Allotment, quotation and trading of New CDIs under the Placement | Wednesday, August 20, 2025 |
*The above timetable reflects the Australian time zone and the dates may change. AVITA Medical reserves the right to amend these dates at its absolute discretion, subject to the Corporations Act (2001) (Cth), the ASX Listing Rules, and other applicable laws. The quotation of the New CDIs is subject to confirmation from the ASX.
About AVITA Medical, Inc.
AVITA Medical® is a leading therapeutic acute wound care company delivering transformative solutions. Our technologies are designed to optimize wound healing, effectively accelerating the time to patient recovery. At the forefront of our platform is the RECELL® System, approved by the FDA for the treatment of thermal burn and trauma wounds. RECELL harnesses the healing properties of a patient’s own skin to create Spray-On Skin™ Cells, offering an innovative solution for improved clinical outcomes at the point-of-care. In the U.S., AVITA Medical also holds the exclusive rights to manufacture, market, sell, and distribute PermeaDerm®, a biosynthetic wound matrix, and the exclusive rights to market, sell, and distribute Cohealyx™, an AVITA Medical-branded collagen-based dermal matrix.
In international markets, the RECELL System is approved to promote skin healing in a wide range of applications including thermal burn and trauma wounds. The RECELL System, excluding RECELL GO®, is TGA-registered in Australia, has received CE mark approval in Europe, and has PMDA approval in Japan.
To learn more, visit www.avitamedical.com.
Notice to U.S. persons: restriction on purchasing CDIs
AVITA Medical is incorporated in the State of Delaware and its CDIs have not been registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”) or the laws of any state or other jurisdiction in the United States. Trading of AVITA Medical’s CDIs on the Australian Securities Exchange (the “ASX”) is not subject to the registration requirements of the Securities Act in reliance on Regulation S under the Securities Act, as supplemented by a related “no action” letter issued by the U.S. Securities and Exchange Commission (the “SEC”) to the ASX in 2000. As a result, the CDIs are “restricted securities” (as defined in Rule 144 under the Securities Act) and may not be sold or otherwise transferred except in transactions exempt from, or not subject to, the registration requirements of the Securities Act. To enforce the transfer restrictions, the CDIs will bear a FOR Financial Product designation on the ASX. This designation restricts CDIs from being purchased by U.S. persons. Finally, any hedging transaction with regard to the CDIs may only be conducted in compliance with the Securities Act.
Investor & Media Contact:
Ben Atkins
Phone +1-805 341 1571
investor@avitamedical.com
media@avitamedical.com
Authorized for release by the Board of Directors of AVITA Medical, Inc.
FAQ
How much did AVITA Medical (RCEL) raise in its Australian equity placement?
What is the purpose of AVITA Medical's 2025 capital raise?
When will the new AVITA Medical CDIs begin trading on the ASX?
What was the pricing of AVITA Medical's 2025 private placement?
When does AVITA Medical expect to achieve free cash flow?
